This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The study examined ROS (10 mg daily), atorvastatin (ATO; 10 mg daily), pravastatin (PRA; 20 mg daily) and simvastatin (SIM; 20 mg daily). Doses were doubled if the low-density lipoprotein level exceeded 115 mg/dL after 12 weeks.
Location/setting
Portugal/primary prevention.
Methods

Analytical approach:
This economic evaluation was based on a probabilistic Markov model that simulated the management of the eligible population and the risk of IHD (myocardial infarction and death). A lifetime horizon (60 years) was adopted. The authors stated that the perspective of the payer was adopted.
Effectiveness data:
The clinical data were derived from multiple sources, which appear to have been identified selectively. Treatment effectiveness was based on head-to-head trials in which ROS was directly compared with another statin. Basically, pooled data from 5 double-blind, randomised, clinical trials (RCTs) were used for the first 12 weeks of treatment. Longer-term data on pravastatin and simvastatin were derived from a single open-label RCT; data on atorvastatin and rosuvastatin were based on a randomized double-blind clinical trial. The impact of LDL levels on IHD events was based on a meta-analysis of 58 selected RCTs. Epidemiological data (mortality rates, life-expectancy and incidence of myocardial infarction) came from Portuguese sources.
Monetary benefit and utility valuations:
: None.
Measure of benefit:
The summary benefit measure was survival (i.e. life-years, LYs). The LYs were estimated using the decision model. An annual discount rate of 5% was applied.
